Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + ipilimumab
- Development stage
- Phase 2
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
nab-paclitaxel + ipilimumab is a combination therapy evaluated for the treatment of metastatic melanoma. It consists of Abraxane (nab-paclitaxel), a nanoparticle albumin-bound formulation of the taxane paclitaxel, and Yervoy (ipilimumab), a recombinant human monoclonal antibody. Nab-paclitaxel functions as a cytotoxic chemotherapy agent by stabilizing microtubules and inhibiting cell division, while ipilimumab acts as an immune checkpoint inhibitor by targeting CTLA-4 to enhance T-cell activation and proliferation. This specific combination was investigated in a Phase II clinical trial (NCT01827111) led by the M.D. Anderson Cancer Center to assess safety and efficacy in patients with advanced or unresectable cutaneous or mucosal melanoma.
- Brand names
- Abraxane + Yervoy
- Other names
- paclitaxel albumin-boundnab-paclitaxelipilimumab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nab-paclitaxel + ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + ipilimumab.